Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-08-10
2009-11-10
Huynh, Phuong (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S069100, C424S184100, C436S008000, C436S015000, C530S324000
Reexamination Certificate
active
07615359
ABSTRACT:
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 4594409 (1986-06-01), Hayashi et al.
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter et al.
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Bishwajit et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958972 (1999-09-01), Hupe et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Yong and Chabot
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7022663 (2006-04-01), Gilbert et al.
patent: 7033582 (2006-04-01), Yong et al.
patent: 7074580 (2006-07-01), Gad et al.
patent: 7163802 (2007-01-01), Gad et al.
patent: 7199098 (2007-04-01), Konfino et al.
patent: 7279172 (2007-10-01), Aharoni et al.
patent: 7407936 (2008-08-01), Eisenbach-Schwartz et al.
patent: 7425332 (2008-09-01), Aharoni et al.
patent: 7429374 (2008-09-01), Klinger
patent: 7495072 (2009-02-01), Dolitzky
patent: 2002/0037848 (2002-03-01), Eisenbach-Schwartz et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2002/0077278 (2002-06-01), Yong et al.
patent: 2002/0107388 (2002-08-01), Vandenbark
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2004/0106554 (2004-06-01), Konfino et al.
patent: 2005/0014694 (2005-01-01), Yong et al.
patent: 2005/0019322 (2005-01-01), Rodriguez et al.
patent: 2005/0038233 (2005-02-01), Gad et al.
patent: 2005/0170004 (2005-08-01), Rosenberger
patent: 2005/0171286 (2005-08-01), Konfino et al.
patent: 2005/0256046 (2005-11-01), Gad et al.
patent: 2006/0052586 (2006-03-01), Dolitzky
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 2007/0007055 (2007-01-01), Schmidt et al.
patent: 2007/0021324 (2007-01-01), Dolitzky et al.
patent: 2007/0021341 (2007-01-01), Sela et al.
patent: 2007/0054857 (2007-03-01), Pinchasi et al.
patent: 3930733 (1991-03-01), None
patent: 0378246 (1990-06-01), None
patent: 0383620 (1990-08-01), None
patent: 0359783 (1995-11-01), None
patent: 1292279 (2003-03-01), None
patent: 0254496 (1990-08-01), None
patent: 336690 (1998-01-01), None
patent: 1690368 (1995-08-01), None
patent: 1469826 (1995-11-01), None
patent: 1182051 (1985-09-01), None
patent: 1664845 (1991-07-01), None
patent: WO 8810120 (1988-12-01), None
patent: WO 9202543 (1992-02-01), None
patent: WO 9403484 (1994-02-01), None
patent: WO 9426774 (1994-11-01), None
patent: WO9526980 (1995-10-01), None
patent: WO9531990 (1995-11-01), None
patent: WO 9531997 (1995-11-01), None
patent: WO 9533475 (1995-12-01), None
patent: US 1996005215 (1996-10-01), None
patent: WO 96/32119 (1996-10-01), None
patent: WO9830227 (1998-07-01), None
patent: WO0005249 (2000-02-01), None
patent: WO0005250 (2000-02-01), None
patent: WO0018794 (2000-04-01), None
patent: WO0020010 (2000-04-01), None
patent: WO0027417 (2000-05-01), None
patent: WO0152878 (2001-07-01), None
patent: WO0160392 (2001-08-01), None
patent: WO0185797 (2001-11-01), None
patent: WO0193828 (2001-12-01), None
patent: WO0193893 (2001-12-01), None
patent: WO0197846 (2001-12-01), None
patent: WO02076503 (2002-10-01), None
patent: US 04036172 (2003-06-01), None
patent: WO03048735 (2003-06-01), None
patent: CA 0301744 (2004-05-01), None
patent: US 0539003 (2006-05-01), None
patent: US 0772865 (2008-01-01), None
patent: SA 0980214 (1999-09-01), None
Sigma catalog p. 1819, 1997.
Andrews et al, Biochem J 91: 222-233, 1964.
Andrews, et al. Biochem J., 1964, 91: 222-233.
Dorling, et al., “Prospects for Xenografting” Curr. Opinions Immunol., 1994, 6, 765-769.
Johnson, “Management of Relapsing/Remitting MS with Copolymer 1 (copaxone)” Chem Abstracts, 1996, 125 (23): 291993 b.
“Copaxone®” in Physician's Desk Reference, Medical Economics Co., Inc., Montvale, NJ, 2002, 3115.
Copaxone® (glatiramer acetate injection), prescribing information(www.copaxone.com/pdf/PrescribingInformation.pdf).
Sigma Catalog, p. 1819, 1997.
U.S. Appl. No. 12/074,106, filed Feb. 22, 2008, Pinchasi et al.
Abramsky, et al., “Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis”,J. Neurol. Sci.,1977, 31, 433-438.
Aharoni, et al., “T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis”,Eur. J. Immunol.,1993, 23, 17-25.
Aharoni, et al., “Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease”,Immunol. Letters,1997, 58, 79-87.
Aharoni, et al., “Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis”,Proc. Natl. Acad. Sci. USA,1997, 94, 10821-10826.
Aharoni, et al., “Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151”, Neurology, 1997, vol. 48, No. 3, A422.
Aharoni, et al., “Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1”,Journal of Neuroimmunology,1998, 91, 135-146.
Alvord, et al., “Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys”,Ann. Neurol.,1979, 6, 469-473.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen”,Israel J. Med. Sci.,1972, 8, 1759-1760.
Arnon, et al., “Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids”,Neurol.,1978, 28, (Abstract).
Arnon, et al., “Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues” inThe Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis(Academic Press, New York, 1980) 105-107.
Arnon, “A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy” inProgress in Multiple Sclerosis Research(Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418.
Arnon, “Experimental
Gad Alexander
Lis Dora
Cooper & Dunham LLP
Huynh Phuong
White John P.
Yeda Research and Development Co. Ltd.
LandOfFree
Copolymer 1 related polypeptides for use as molecular weight... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Copolymer 1 related polypeptides for use as molecular weight..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Copolymer 1 related polypeptides for use as molecular weight... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4080298